Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 55, Issue 6, 2016, Pages 456-468.e4

  Park, Su Young ^a   Cervesi, Chiara ^a,b   Galling, Britta ^a   Molteni, Silvia ^d   Walyzada, Frozan ^a   Ameis, Stephanie H ^e   Gerhard, Tobias ^f   Olfson, Mark ^g   Correll, Christoph U ^a,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF PAVIA   (Italy)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f RUTGERS UNIVERSITY   (United States)

^g NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

adolescent; antipsychotic; autism; child; intellectual disability

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

AUTISM; CROSS-SECTIONAL STUDY; DATA BASE; HUMAN; INTELLECTUAL IMPAIRMENT; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; SYSTEMATIC REVIEW; ADOLESCENT; CHILD; CLINICAL PRACTICE; PRESCHOOL CHILD; PRESCRIPTION; STATISTICS AND NUMERICAL DATA; TRENDS;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; AUTISM SPECTRUM DISORDER; CHILD; CHILD, PRESCHOOL; DRUG PRESCRIPTIONS; HUMANS; INTELLECTUAL DISABILITY; PRACTICE PATTERNS, PHYSICIANS';

EID: 84991228030     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2016.03.012     Document Type: Review

References (79)

1. 1 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th Edition, Text Revision. 2000, American Psychiatric Association, Arlington, VA.
2. 2 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th Edition. 2013, American Psychiatric Association, Arlington, VA.
3. 3 Fombonne, E., Epidemiology of pervasive developmental disorders. Pediatr Res 65 (2009), 591–598.
4. 4 Elsabbagh, M., Divan, G., Koh, Y.J., et al. Global prevalence of autism and other pervasive developmental disorders. Autism Res 5 (2012), 160–179.
5. 5 Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders among children aged 8 years–Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2010. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ss6302a1.htm. Accessed March 1, 2013.
6. 6 Charman, T., The prevalence of the autism spectrum disorders: recent evidence and future challenges. Eur Child Adoles Psychiatry 11 (2002), 249–256.
7. 7 Matson, J.L., Nebel-Schwalm, M.S., Comorbid psychopathology with autism spectrum disorder in children: an overview. Res Dev Disabil 28 (2007), 341–352.
8. 8 Mattila, M.L., Hurtig, T., Haapsamo, H., et al. Comorbid psychiatric disorders associated with Asperger syndrome/high-functioning autism: a community- and clinic-based study. J Autism Dev Disord 40 (2010), 1080–1093.
9. 9 Charman, T., Pickles, A., Simonoff, E., Chandler, S., Loucas, T., Baird, G., IQ in children with autism spectrum disorders: data from the Special Needs and Autism Project (SNAP). Psychol Med 41 (2011), 619–627.
10. 10 Mazefsky, C.A., Oswald, D.P., Day, T.N., Eack, S.M., Minshew, N.J., Lainhart, J.E., ASD, a psychiatric disorder, or both? Psychiatric diagnoses in adolescents with high-functioning ASD. J Clin Child Adolesc Psychol 41 (2012), 516–523.
11. 11 Skokauskas, N., Gallagher, L., Mental health aspects of autistic spectrum disorders in children. J Intellect Disabil Res 56 (2012), 248–257.
12. 12 Ameis, S., Szatmari, P., Common psychiatric comorbidities in autism spectrum disorder and their assessment. Anagnostou, E., Brian, J., (eds.) Clinician's Manual on Autism Spectrum Disorder, 2015, Springer Healthcare, Basel, Switzerland.
13. 13 Sheehan, R., Hassiotis, A., Walters, K., Osborn, D., Strydom, A., Horsfall, L., Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ, 351, 2015, h4326.
14. 14 Hampson, D.R., Gholizadeh, S., Pacey, L.K., Pathways to drug development for autism spectrum disorders. Clin Pharmacol Ther 91 (2012), 189–200.
15. 15 McCracken, J., McGough, J., Shah, B., et al. Risperidone in children with autism and serious behavior problems. N Engl J Med 347 (2002), 314–321.
16. 16 Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 347 (2002), 314–321.
17. 17 Shea, S., Turgay, A., Carroll, A., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114 (2004), e634–e641.
18. 18 Marcus, R.N., Owen, R., Kame, L., et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48 (2009), 1110–1119.
19. 19 Owen, R., Sikich, L., Marcus, R.N., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124 (2009), 1533–1540.
20. 20 Correll, C.U., Kratochvil, C.J., March, J.S., Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry 72 (2011), 655–670.
21. 21 Oswald, D.P., Sonenklar, N.A., Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol 17 (2007), 348–355.
22. 22 Bearss, K., Johnson, C., Smith, T., et al. Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder: a randomized clinical trial. JAMA 313 (2015), 1524–1533.
23. 23 Esbensen, A.J., Greenberg, J.S., Seltzer, M.M., Aman, M.G., A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. J Autism Dev Disord 39 (2009), 1339–1349.
24. 24 Food and Drug Administration. NDA 20–272 / S-036, 20-588 / S-024, 21-444 / S-008: Final Agreed-Upon Labeling. 2006. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021444s008s015, 020588s024s028s029, 020272s036s041lbl.pdf. Accessed March 1, 2013.
25. 25 Food and Drug Administration. New indication approval for Abilify (aripiprazole). Supplemental Letter. NDA 021436/S-027. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021436s027ltr.pdf. 2009. Accessed March 1, 2013.
26. 26 Memari, A.H., Ziaee, V., Beygi, S., Moshayedi, P., Mirfazeli, F.S., Overuse of psychotropic medications among children and adolescents with autism spectrum disorders: perspective from a developing country. Res Dev Disabil 33 (2012), 563–569.
27. 27 Correll, C.U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J.M., Malhotra, A.K., Cardiometabolic risk of atypical antipsychotics during first-time use in children and adolescents. JAMA 302 (2009), 1763–1771.
28. 28 De Hert, M., Detraux, J., van Winkel, R., Yu, W., Correll, C.U., Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8 (2011), 114–126.
29. 29 De Hert, M., Dobbelaere, M., Sheridan, E.M., Cohen, D., Correll, C.U., Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 26 (2011), 144–158.
30. 30 Alessi-Severini, S., Biscontri, R.G., Collins, D.M., Sareen, J., Enns, M.W., Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry 57 (2012), 52–58.
31. 31 Baeza, I., de la Serna, E., Calvo-Escalona, R., et al. Antipsychotic use in children and adolescents: a 1-year follow-up study. J Clin Psychopharmacol 34 (2014), 613–619.
32. 32 Maršanić, V.B., Dodig-Ćurković, K., Juretić, Z., Outpatient treatment of children and adolescents with antipsychotic drugs in Croatia. Nord J Psychiatry 66 (2012), 2–7.
33. 33 Chen, C.Y., Gerhard, T., Winterstein, A.G., Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 19 (2009), 187–195.
34. 34 Christian, R.B., Farley, J.F., Sheitman, B., et al. A+KIDS, a Web-based antipsychotic registry for North Carolina youths: an alternative to prior authorization. Psychiatr Serv 64 (2013), 893–900.
35. 35 Connolly, J.G., Toomey, T.J., Schneeweiss, M.C., Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011. Psychiatr Serv 66 (2015), 604–609.
36. 36 Constantine, R.J., Tandon, R., McPherson, M., Andel, R., Early diagnoses and psychotherapeutic medication treatment experiences of a cohort of children under 6 years old who received antipsychotic treatment in Florida's Medicaid program. J Child Adolesc Psychopharmacol 21 (2011), 79–84.
37. 37 Cooper, W.O., Hickson, G.B., Fuchs, C., Arbogast, P.G., Ray, W.A., New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 158 (2004), 753–759.
38. 38 Crystal, S., Olfson, M., Huang, C., Pincus, H., Gerhard, T., Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood) 28 (2009), w770–w781.
39. 39 Deurell, M., Weischer, M., Pagsberg, A.K., Labianca, J., The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey. Nord J Psychiatry 62 (2008), 472–480.
40. 40 DosReis, S., Yoon, Y., Rubin, D.M., Riddle, M.A., Noll, E., Rothbard, A., Antipsychotic treatment among youth in foster care. Pediatrics 128 (2011), e1459–e1466.
41. 41 Findling, R.L., Horwitz, S.M., Birmaher, B., et al. Clinical characteristics of children receiving antipsychotic medication. J Child Adolesc Psychopharmacol 21 (2011), 311–319.
42. 42 Harrison-Woolrych, M., Garcia-Quiroga, J., Ashton, J., Herbison, P., Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Saf 30 (2007), 569–579.
43. 43 Hong, I.S., Bishop, J.R., Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother 44 (2010), 1171–1180.
44. 44 Hsu, Y.C., Chien, I.C., Tan, H.K., et al. Trends, correlates, and disease patterns of antipsychotic use among children and adolescents in Taiwan. Soc Psychiatry Psychiatr Epidemiol 48 (2013), 1889–1896.
45. 45 Linton, D., Procyshyn, R.M., Elbe, D., Lee, L.H., Barr, A.M., A retrospective study of antipsychotic drug switching in a pediatric population. BMC Psychiatry, 8;13, 2013, 248.
46. 46 Matone, M., Localio, R., Huang, Y.S., DosReis, S., Feudtner, C., Rubin, D., The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children. Health Serv Res 47 (2012), 1836–1860.
47. 47 Olfson, M., Crystal, S., Huang, C., Gerhard, T., Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry 49 (2010), 13–23.
48. 48 Panagiotopoulos, C., Ronsley, R., Davidson, J., Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Can J Psychiatry 54 (2009), 743–749.
49. 49 Patel, N.C., Crismon, M.L., Shafer, A., Diagnoses and antipsychotic treatment among youths in a public mental health system. Ann Pharmacother 40 (2006), 205–211.
50. 50 Pathak, P., West, D., Martin, B.C., Helm, M.E., Henderson, C., Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv 61 (2010), 123–129.
51. 51 Procyshyn, R.M., Su, J., Elbe, D., et al. Prevalence and patterns of antipsychotic use in youth at the time of admission and discharge from an inpatient psychiatric facility. J Clin Psychopharmacol 34 (2014), 17–22.
52. 52 Rettew, D.C., Greenblatt, J., Kamon, J., et al. Antipsychotic medication prescribing in children enrolled in Medicaid. Pediatrics 135 (2015), 658–665.
53. 53 Ronsley, R., Rayter, M., Smith, D., Davidson, J., Panagiotopoulos, C., Metabolic monitoring training program implementation in the community setting was associated with improved monitoring in second-generation antipsychotic-treated children. Can J Psychiatry 57 (2012), 292–299.
54. 54 Ronsley, R., Scott, D., Warburton, W.P., et al. A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011. Can J Psychiatry 58 (2013), 361–369.
55. 55 Saldaña, S.N., Keeshin, B.R., Wehry, A.M., et al. Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization. Pharmacotherapy 34 (2014), 836–844.
56. 56 Zito, J.M., Burcu, M., Ibe, A., Safer, D.J., Magder, L.S., Antipsychotic use by Medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade. Psychiatr Serv 64 (2013), 223–229.
57. 57 Birnbaum, M.L., Saito, E., Gerhard, T., et al. Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications. Curr Psychiatry Rep 15 (2013), 382–395.
58. 58 Olfson, M., Blanco, C., Liu, S.M., Wang, S., Correll, C.U., National trends in the office-based treatment of children and adolescents, and adults with antipsychotics. Arch Gen Psychiatry 69 (2012), 1247–1256.
59. 59 Reichow, B., Steiner, A.M., Volkmar, F., Cochrane review: social skills groups for people aged 6 to 21 with autism spectrum disorders (ASD). Evid Based Child Health 8 (2013), 266–315.
60. 60 Kasari, C., Freeman, S., Paparella, T., Joint attention and symbolic play in young children with autism: a randomized controlled intervention study. J Child Psychol Psychiatry 47 (2006), 611–620.
61. 61 Kasari, C., Gulsrud, A.C., Wong, C., Kwon, S., Locke, J., Randomized controlled caregiver mediated joint engagement intervention for toddlers with autism. J Autism Dev Disord 40 (2010), 1045–1056.
62. 62 Sofronoff, K., Attwood, T., Hinton, S., A randomised controlled trial of a CBT intervention for anxiety in children with Asperger syndrome. J Child Psychol Psychiatry 46 (2005), 1152–1160.
63. 63 Chalfant, A.M., Rapee, R., Carroll, L., Treating anxiety disorders in children with high functioning autism spectrum disorders: a controlled trial. J Autism Dev Disord 37 (2007), 1842–1857.
64. 64 Reaven, J., Blakeley-Smith, A., Culhane-Shelburne, K., Hepburn, S., Group cognitive behavior therapy for children with high-functioning autism spectrum disorders and anxiety: a randomized trial. J Child Psychol Psychiatry 53 (2012), 410–419.
65. 65 McNally Keehn, R.H., Lincoln, A.J., Brown, M.Z., Chavira, D.A., The Coping Cat program for children with anxiety and autism spectrum disorder: a pilot randomized controlled trial. J Autism Dev Disord 43 (2013), 57–67.
66. 66 Correll, C.U., Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47 (2008), 9–20.
67. 1 Aman, M.G., Lam, K.S., Collier-Crespin, A., Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord 33 (2003), 527–534.
68. 2 Bachmann, C.J., Manthey, T., Kamp-Becker, I., Glaeske, G., Hoffmann, F., Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany. Res Dev Disabil 34 (2013), 2551–2563.
69. 3 Esbensen, A.J., Greenberg, J.S., Seltzer, M.M., Aman, M.G., A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. J Autism Dev Disord 39 (2009), 1339–1349.
70. 4 Frazier, T.W., Shattuck, P.T., Narendorf, S.C., Cooper, B.P., Wagner, M., Spitznagel, E.L., Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 21 (2011), 571–579.
71. 5 Langworthy-Lam, K.S., Aman, M.G., Van Bourgondien, M.E., Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol 12 (2002), 311–321.
72. 6 Logan, S.L., Carpenter, L., Leslie, R.S., et al. Rates and predictors of adherence to psychotropic medications in children with autism spectrum disorders. J Autism Dev Disord 44 (2014), 2931–2948.
73. 7 Mandell, D.S., Morales, K.H., Marcus, S.C., Stahmer, A.C., Doshi, J., Polsky, D.E., Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics 121 (2008), e441–e448.
74. 8 Matone, M., Localio, R., Huang, Y.S., DosReis, S., Feudtner, C., Rubin, D., The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children. Health Serv Res 47 (2012), 1836–1860.
75. 9 Memari, A.H., Ziaee, V., Beygi, S., Moshayedi, P., Mirfazeli, F.S., Overuse of psychotropic medications among children and adolescents with autism spectrum disorders: perspective from a developing country. Res Dev Disabil 33 (2012), 563–569.
76. 10 Murray, M.L., Hsia, Y., Glaser, K., et al. Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology (Berl) 231 (2014), 1011–1021.
77. 11 Oswald, D.P., Sonenklar, N.A., Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol 17 (2007), 348–355.
78. 12 Rosenberg, R.E., Mandell, D.S., Farmer, J.E., Law, J.K., Marvin, A.R., Law, P.A., Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008. J Autism Dev Disord 40 (2010), 342–351.
79. 13 Steinhausen, H.C., Bisgaard, C., Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark. Acta Psychiatr Scand 129 (2014), 221–231.